Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

20195,806 citationsJournal Articlebronze Open Access

Authors

Vlado Perkovic · North Shore Hospital

Meg Jardine · Concord Repatriation General Hospital

Bruce Neal · The University of Sydney

Séverine Bompoint · UNSW Sydney

Hiddo J.L. Heerspink · University of Groningen

David M. Charytan · Baim Institute for Clinical Research

Robert Edwards

Abstract

In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; CREDENCE ClinicalTrials.gov number, NCT02065791.).

Topics & Keywords

Diabetes Treatment and Management Pancreatic function and diabetes Potassium and Related Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 24, pp. 2295-2306

DOI: 10.1056/nejmoa1811744

Field-Weighted Citation Impact: 490.07